Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol

Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Lauve Rachel Tchokouaha Yamthe [verfasserIn] Trudy Janice Philips [verfasserIn] Dorcas Osei-Safo [verfasserIn] Paul Toukam Djouonzo [verfasserIn] Odame Agyapong [verfasserIn] Eunice Dotse [verfasserIn] Patrick Valere Tsouh Fokou [verfasserIn] Samuel Kojo Kwofie [verfasserIn] Fabrice Fekam Boyom [verfasserIn] Alexander Kwadwo Nyarko [verfasserIn] Regina Appiah-Opong [verfasserIn] Michael David Wilson [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase

Übergeordnetes Werk:	In: Future Drug Discovery - Future Science Ltd, 2021, 2(2020), 3
Übergeordnetes Werk:	volume:2 ; year:2020 ; number:3

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.4155/fdd-2020-0002

Katalog-ID:	DOAJ010639667

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ010639667
003	DE-627
005	20230310030810.0
007	cr uuu---uuuuu
008	230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.4155/fdd-2020-0002 \|2 doi
035			\|a (DE-627)DOAJ010639667
035			\|a (DE-599)DOAJc6515c78f5194194897dc0679e59be9c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RS1-441
100	0		\|a Lauve Rachel Tchokouaha Yamthe \|e verfasserin \|4 aut
245	1	0	\|a Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.
650		4	\|a antileishmanial activity
650		4	\|a fucosterol
650		4	\|a in silico mechanism of binding
650		4	\|a Sargassum vulgare
650		4	\|a trypanothione reductase
653		0	\|a Pharmacy and materia medica
700	0		\|a Trudy Janice Philips \|e verfasserin \|4 aut
700	0		\|a Dorcas Osei-Safo \|e verfasserin \|4 aut
700	0		\|a Paul Toukam Djouonzo \|e verfasserin \|4 aut
700	0		\|a Odame Agyapong \|e verfasserin \|4 aut
700	0		\|a Eunice Dotse \|e verfasserin \|4 aut
700	0		\|a Patrick Valere Tsouh Fokou \|e verfasserin \|4 aut
700	0		\|a Samuel Kojo Kwofie \|e verfasserin \|4 aut
700	0		\|a Fabrice Fekam Boyom \|e verfasserin \|4 aut
700	0		\|a Alexander Kwadwo Nyarko \|e verfasserin \|4 aut
700	0		\|a Regina Appiah-Opong \|e verfasserin \|4 aut
700	0		\|a Michael David Wilson \|e verfasserin \|4 aut
773	0	8	\|i In \|t Future Drug Discovery \|d Future Science Ltd, 2021 \|g 2(2020), 3 \|w (DE-627)1760793973 \|x 26313316 \|7 nnns
773	1	8	\|g volume:2 \|g year:2020 \|g number:3
856	4	0	\|u https://doi.org/10.4155/fdd-2020-0002 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/c6515c78f5194194897dc0679e59be9c \|z kostenfrei
856	4	0	\|u https://www.future-science.com/doi/10.4155/fdd-2020-0002 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2631-3316 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 2 \|j 2020 \|e 3

Indexfelder

author_variant	l r t y lrty t j p tjp d o s dos p t d ptd o a oa e d ed p v t f pvtf s k k skk f f b ffb a k n akn r a o rao m d w mdw
matchkey_str	article:26313316:2020----::niesmnaefcsfagsuvlaerdcsnpeitootyaohoee
hierarchy_sort_str	2020
callnumber-subject-code	RS
publishDate	2020
allfields	10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3
spelling	10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3
allfields_unstemmed	10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3
allfieldsGer	10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3
allfieldsSound	10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3
language	English
source	In Future Drug Discovery 2(2020), 3 volume:2 year:2020 number:3
sourceStr	In Future Drug Discovery 2(2020), 3 volume:2 year:2020 number:3
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica
isfreeaccess_bool	true
container_title	Future Drug Discovery
authorswithroles_txt_mv	Lauve Rachel Tchokouaha Yamthe @@aut@@ Trudy Janice Philips @@aut@@ Dorcas Osei-Safo @@aut@@ Paul Toukam Djouonzo @@aut@@ Odame Agyapong @@aut@@ Eunice Dotse @@aut@@ Patrick Valere Tsouh Fokou @@aut@@ Samuel Kojo Kwofie @@aut@@ Fabrice Fekam Boyom @@aut@@ Alexander Kwadwo Nyarko @@aut@@ Regina Appiah-Opong @@aut@@ Michael David Wilson @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	1760793973
id	DOAJ010639667
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010639667</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310030810.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4155/fdd-2020-0002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010639667</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc6515c78f5194194897dc0679e59be9c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Lauve Rachel Tchokouaha Yamthe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antileishmanial activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fucosterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">in silico mechanism of binding</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sargassum vulgare</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trypanothione reductase</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Trudy Janice Philips</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dorcas Osei-Safo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Toukam Djouonzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Odame Agyapong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eunice Dotse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Valere Tsouh Fokou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samuel Kojo Kwofie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrice Fekam Boyom</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Kwadwo Nyarko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Regina Appiah-Opong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael David Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Future Drug Discovery</subfield><subfield code="d">Future Science Ltd, 2021</subfield><subfield code="g">2(2020), 3</subfield><subfield code="w">(DE-627)1760793973</subfield><subfield code="x">26313316</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c6515c78f5194194897dc0679e59be9c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.future-science.com/doi/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2631-3316</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Lauve Rachel Tchokouaha Yamthe
spellingShingle	Lauve Rachel Tchokouaha Yamthe misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
authorStr	Lauve Rachel Tchokouaha Yamthe
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760793973
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RS1-441
illustrated	Not Illustrated
issn	26313316
topic_title	RS1-441 Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase
topic	misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica
topic_unstemmed	misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica
topic_browse	misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Future Drug Discovery
hierarchy_parent_id	1760793973
hierarchy_top_title	Future Drug Discovery
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760793973
title	Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
ctrlnum	(DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c
title_full	Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
author_sort	Lauve Rachel Tchokouaha Yamthe
journal	Future Drug Discovery
journalStr	Future Drug Discovery
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Lauve Rachel Tchokouaha Yamthe Trudy Janice Philips Dorcas Osei-Safo Paul Toukam Djouonzo Odame Agyapong Eunice Dotse Patrick Valere Tsouh Fokou Samuel Kojo Kwofie Fabrice Fekam Boyom Alexander Kwadwo Nyarko Regina Appiah-Opong Michael David Wilson
container_volume	2
class	RS1-441
format_se	Elektronische Aufsätze
author-letter	Lauve Rachel Tchokouaha Yamthe
doi_str_mv	10.4155/fdd-2020-0002
author2-role	verfasserin
title_sort	antileishmanial effects of sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
callnumber	RS1-441
title_auth	Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
abstract	Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.
abstractGer	Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.
abstract_unstemmed	Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
url	https://doi.org/10.4155/fdd-2020-0002 https://doaj.org/article/c6515c78f5194194897dc0679e59be9c https://www.future-science.com/doi/10.4155/fdd-2020-0002 https://doaj.org/toc/2631-3316
remote_bool	true
author2	Trudy Janice Philips Dorcas Osei-Safo Paul Toukam Djouonzo Odame Agyapong Eunice Dotse Patrick Valere Tsouh Fokou Samuel Kojo Kwofie Fabrice Fekam Boyom Alexander Kwadwo Nyarko Regina Appiah-Opong Michael David Wilson
author2Str	Trudy Janice Philips Dorcas Osei-Safo Paul Toukam Djouonzo Odame Agyapong Eunice Dotse Patrick Valere Tsouh Fokou Samuel Kojo Kwofie Fabrice Fekam Boyom Alexander Kwadwo Nyarko Regina Appiah-Opong Michael David Wilson
ppnlink	1760793973
callnumber-subject	RS - Pharmacy
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.4155/fdd-2020-0002
callnumber-a	RS1-441
up_date	2024-07-03T15:56:35.523Z
_version_	1803573993691676672
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010639667</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310030810.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4155/fdd-2020-0002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010639667</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc6515c78f5194194897dc0679e59be9c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Lauve Rachel Tchokouaha Yamthe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antileishmanial activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fucosterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">in silico mechanism of binding</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sargassum vulgare</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trypanothione reductase</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Trudy Janice Philips</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dorcas Osei-Safo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Toukam Djouonzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Odame Agyapong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eunice Dotse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Valere Tsouh Fokou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samuel Kojo Kwofie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrice Fekam Boyom</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Kwadwo Nyarko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Regina Appiah-Opong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael David Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Future Drug Discovery</subfield><subfield code="d">Future Science Ltd, 2021</subfield><subfield code="g">2(2020), 3</subfield><subfield code="w">(DE-627)1760793973</subfield><subfield code="x">26313316</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c6515c78f5194194897dc0679e59be9c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.future-science.com/doi/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2631-3316</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield></datafield></record></collection>
score	7.399705

Nicht das Richtige dabei?

Schreiben Sie uns!

Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?